Search

Fibralign Announces Completion of First Surgery in the Stanford Led Clinical Trial for Breast Cancer

Fibralign Corporation (“Fibralign”), a developer of advanced therapeutic medical devices, announced today that the first surgery has been performed in a clinical study of secondary lymphedema treatment being conducted at Stanford University. This investigator-initiated study, which recently received FDA approval, aims to evaluate the efficacy of a new surgical device, Fibralign’s BioBridge® Collagen Matrix, in supporting and guiding lymphatic repair in patients with acquired lymphedema of upper and lower extremities. Stanford is currently enrolling patients and expects to have at least 36 patients in the study. “We are pleased to receive FDA approval to move forward with this important s

WHO WE ARE

Fibralign Corporation is a developer of advanced therapeutic devices that utilizes Nanoweave ®, a proprietary scaffolding technology for addressing unmet medical needs.

Read More >

QUICK LINKS
GET IN TOUCH